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case-control studies
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Background: Genetic polymorphism (rs762551A>C) in gene encoding cytochrome P450 1A2 (CYP1A2) has been
shown to influence the inducibility of CYP1A2 expression and thus might be associated with risk of several types of
human cancer. However, the results of previous studies on the associations of this polymorphism with risk of
cancer are not all consistent. To clarify the potential contribution of CYP1A2 rs762551 to cancer risk, we performed a
meta-analysis of the published case–control studies.
Methods: We used PubMed, Embase, OVID, ScienceDirect, and Chinese National Knowledge Infrastructure
databases to identify the related publications for this meta-analysis. The pooled odds ratio (OR) and 95% confidence
interval (CI) were calculated using random effect model to evaluate the association of rs762551 with cancer risk. A
χ2-based Q-test was used to examine the heterogeneity assumption and the funnel plot and Egger’s test were used
to examine the potential publication bias. The leave-one-out sensitivity analysis was conducted to determine
whether our assumptions or decisions have a major effect on the results of the review.
Results: Our analysis of 19 eligible case–control studies showed a significant association between rs762551C variant
with risk of cancer in the genetic model of CC versus AA (OR = 1.30, 95% CI = 1.02-1.64) and the dominant model
(OR = 1.19, 95% CI = 1.04-1.36). In subgroup analysis based on ethnicity, the rs762551CC genotype was associated
with increased cancer risk (OR = 1.29, 95% CI = 1.27-1.63 in co-dominate model and OR = 1.17, 95% CI = 1.02-1.34
in dominant model in Caucasians, but not in Asians and the mixed population.
Conclusion: These results suggested that CYP1A2 rs762551 polymorphism is likely to be associated with
susceptibility to cancer in Caucasians.
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The cytochromes P450 (CYPs) played an important role
in the development of various cancers, since they involved
in the metabolic transformation of numerous endogenous
and exogenous compounds including carcinogens and
anti-cancer drugs [1]. Cytochrome P450 1A2 (CYP1A2),
as one of important CYP enzymes, is responsible for
the metabolic activation of pro-carcinogens such as
heterocyclic aromatic amines (HAA), polycyclic aromatic
hydrocarbons (PAHs) and 4-methylnitrosamino-1-(3-* Correspondence: yuanjx@heuu.edu.cn
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reproduction in any medium, provided the orpyridyl)-1-butanone (NNK) and further contributes
to the risk of cancer [2,3].
CYP1A2 gene has been mapped on chromosome
15q24.1 and head to head shares a bidirectional pro-
moter with CYP1A1 gene [4]. It has been demonstrated
that the expression of CYP1A2 existed large inter-
individual variability in the liver [5] and it is believed
that the expression of CYP1A2 is regulated by constitu-
tive expression and inducible expression from environ-
mental chemicals [3,6].
CYP1A2 is highly polymorphic and there are more than
200 polymorphisms existed in CYP1A2 gene region
according to NCBI dbSNP database (http://www.ncbi.nlm.
nih.gov) and SNP500Cancer (http://variatgps.nci.nih.gov).td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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-164A>C polymorphism (CYP1A2*1F; rs762551) [7,8],
which is located in the intron1 of CYP1A2. There also
have several reported studied three common variations,
that is -3860G>A polymorphism (CYP1A2*1C; rs2069514)
[8,9], -739G>T polymorphism (rs2069526) [8,10] and
1545T>C polymorphism (rs2470890) [10,11]. These poly-
morphisms may be related to altered inducibility of
CYP1A2 expression by environmental chemicals and con-
sequently influence the individual susceptibility to certain
cancer. For example, the CYP1A2 rs2069514 A allele has
been demonstrated to associated with decreased enzyme
activity in smokers and CYP1A2 rs762551 polymorphism
is also associated with altered expression of CYP1A2 by
cigarette smoking [12-14].
Recently, many studies have investigated the associ-
ation of CYP1A2 polymorphisms and the risk of various
cancers, including lung cancer, breast cancer, colorectal
cancer, stomach cancer and others in various popula-
tions [15-18]. However, the results of these studies are
not consistent and inconclusive. Considering the role of
CYP1A2 in defending against environmental carcinogens
and in the development of cancers, we performed a sys-
tematic meta-analysis from all eligible studies to address
the overall risk of CYP1A2 variants in the development
of all cancers involved.
Methods
Identification and eligibility of relevant studies
Remote PubMed, Embase, OVID, ScienceDirect, and
Chinese National Knowledge Infrastructure database (bet-
ween January 2003 and December 2011) was searched using
the search terms: CYP1A2/P4501A2/phase II enzymes,
polymorphism/polymorphisms/genotype and cancer/
carcinoma/adenomas to identify all publications, which
investigated the association of the CYP1A2 polymorphism
with cancer risk in all ethnic populations. We evaluated
the titles and abstracts of all relevant papers, but excluded
case reports, editorials and reviews. All publications in
English language with available full text matching the eli-
gible criteria were retrieved. For inclusion in this meta-
analysis, the identified articles had to provide information
on the following: (1) using a case–control design, (2) suffi-
cient data for examining an odds ratio (OR) with 95% con-
fidence interval (CI) and (3) was a study of the CYP1A2
rs762551 polymorphism and cancer risk, (4) genotype dis-
tributions of polymorphism are consistent with hardy-
Weinberg Equilibrium (HWE). In addition, we checked
the references of relevant reviews and eligible articles that
our search retrieved by two investigators independently.
Methods for quantitative analysis
We examined the association between CYP1A2 rs762551
A>C polymorphism and the risk of cancer by calculatingpooled odds ratio (ORs) and 95% confidence intervals
(CI) in genetic model of CC versus AA, dominant
model (CC+CA versus AA) and recessive model (CC
versus CA+AA). The significance of pooled OR was tested
by Z test. The χ2-based Q-test was also used to examine
the heterogeneity assumption [19]. If studies’ findings only
differ by the sampling (P≥0.05), a fixed-effects model
could be used to calculate the combined OR. By contrast,
if the P value of the Q tests is below 0.05, which showed
that the study results statistically differ by heterogeneous
case and sampling, a random-effects model could be more
suitable. Since we used accumulating data from a series of
studies, which had been conducted by researchers opera-
ting independently, the random model was more easily
justified than the fixed model [20,21]. The summary OR
and 95% CI were calculated under the random effect
model.
The leave-one-out sensitivity analysis was conducted
to determine whether our assumptions or decisions have
a major effect on the results of the review by omitting
each study (one at a time) [22]. Furthermore, subgroup
analyses were performed to test whether the effect size
varied by the ethnicity and the source of control popula-
tion. To evaluate the published bias, we used funnel plot
analysis, which is graphical display of sample size plotted
against effect size for the studies included in a meta-
analysis [23]. To test for funnel plot asymmetry, Egger’s
test was performed [24]. All of calculations were per-
formed using R program.
Results
Characteristics of meta-analyses database
After preliminary screening as of 15 December 2011,
there were 53 relevant publications fitting the key terms.
We excluded 34 studies by (1) no related CYP1A2 poly-
morphism, (2) no cancer case–control design, (3) review
articles [25,26], (4) no usable genotype data [27-30] and
included 19 studies [7-11,16-18,31-41] in this meta-
analysis (Figure 1 and Table 1). Overall, the studies
involved in 8,218 cases and 11,165 controls. The geno-
type distributions for CYP1A2 rs762551 polymorphism
are shown in Table 2.
The characteristics of populations and cancer types of
final 19 publications were listed in Table 1. This meta-
analysis involved in 5 breast cancer studies, 5 lung cancer
studies, 4 colorectal cancer studies and 5 studies with other
cancer types. Of these, there were 10 studies conducted in
Caucasian, 7 studies in Asian, 1 study in Tunisian,
and 1 study included multiple ethnicities. There were 6
population-based studies, 12 hospital-based studies, and 1
study with mixed controls study. Variant genotyping
methods were used, which included polymerase chain
reaction restriction fragment length polymorphism assay
(PCR-RFLP) in 14 studies, TaqMan assay, MassARRAY,
Figure 1 The flow chat for study identification.
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known method in one study each. Overall, the genotyping
frequencies of CYP1A2 rs762551 polymorphism were in
agreement with the Hardy-Weinberg equilibrium in both
cases and controls.
Quantitative synthesis
Regarding CYP1A2 rs762551 polymorphism, the eligible
studies involved in 8218 cases and 11165 controls. For
each study, we investigated the association based on the
assumption of different inheritance models of CYP1A2Table 1 Characteristics of the studies included in the meta-an
Author Year Country Ethnicity Cancer type
Khvostova [7] 2011 Russia Caucasian Breast
MARIE-GENICA [31] 2010 German Caucasian Breast
Singh [8] 2010 India Asian Lung
Sangrajrang [16] 2009 Thailand Asian Breast
B0chir [9] 2009 Tunisia Tunisian Lung
Kobayashi [17] 2009 Japan Asian Stomach
Altayli [32] 2009 Turkey Caucasian Bladder
Aldrich [33] 2009 USA Mixed Lung
Saebo [35] 2008 Norway Caucasian Colorectal
Suziki [34] 2008 USA Caucasian Pancreatic
Yoshida [36] 2007 Japan Asian Colorectal
Osawa [18] 2007 Japan Asian Lung
Gemignani [10] 2007 Italy Caucasian Lung
Kotsopoulos [37] 2007 Canada Caucasian Breast
Bae [40] 2006 Korea Asian Colorectal
Long [38] 2006 China Asian Breast
Li [39] 2006 USA Caucasian Pancreatic
Landi [11] 2005 spain Caucasian Colorectal
Goodman [41] 2003 USA Caucasian Ovarian
PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphis; APEXrs762551 A>C polymorphism. In all inheritance models
of rs762551 polymorphism, due to the between-study
heterogeneity in the individual studies (all P for Q test
< 0.01 and I2>25%), the random-effect model was used
to analyze the data [42]. We identified that rs762551
polymorphism had a weak correlation with the risk of
cancer (CC versus AA, OR = 1.30, 95% CI = 1.02-1.64;
dominant model, OR = 1.19, 95% CI = 1.04-1.36), but
not in recessive model (OR = 1.19, 95% CI = 0.99-1.44)
(Figure 2 and Table 2).
Several subgroup analyses were also performed
according to the population ethnicity, cancer type, or
source of control population (Table 2). When we ana-
lyzed the relationship of rs762551 polymorphism and
cancer risk in different ethnicity subgroup. Our data
showed that rs762551 A>C polymorphism increased the
cancer risk (CC versus AA, OR = 1.29, 95% CI = 1.27-
1.63; dominant model, OR = 1.17, 95% CI = 1.02-1.34)
in Caucasians, but not in Asians (CC versus AA, OR =
1.27, 95% CI = 0.83-1.93; dominant model, OR = 1.24,
95% CI = 0.93-1.66) and in other mixed population (CC
versus AA, OR = 1.34, 95% CI = 0.14-12.95; dominant
model, OR = 0.87, 95% CI = 0.17-4.40). In recessive ge-
netic model, our study didn’t show any significant cor-
relation between rs762551 polymorphism and the cancer
risk with OR (95% CI) of 1.19 (0.98-1.45), 1.10 (0.76-1.59)
and 1.68 (0.44-6.35) in Caucasians, Asians and otheralysis
Cases Controls Source of controls Genotype method
323 526 Hospital PCR-RFLP
3147 5485 Population PCR-RFLP
200 200 Population PCR-RFLP
552 483 Hospital TaqMan
101 98 Hospital PCR-RFLP
141 286 Hospital MassARRAY
135 128 Hospital PCR-RFLP
113 299 Mixed Not defined
198 222 Hospital PCR-RFLP
649 585 Population PCR-RFLP
64 111 Hospital PCR-RFLP
103 111 Hospital PCR-RFLP
297 310 Hospital Microarray
170 241 Hospital PCR-RFLP
111 93 Hospital PCR-RFLP
1082 1139 Population PCR-RFLP
307 333 Population PCR-RFLP
361 321 Hospital APEX
164 194 Population PCR-RFLP
, arrayed primer exension.
Table 2 CYP1A2 rs762551 polymorphism and cancer risk stratified by characteristics of studies




Total AA AC CC OR (95% CI) OR (95% CI) OR (95% CI)
All 8218/11165 3750/5374 3567/4720 901/1071 1.30(1.02-1.64)* 1.19(1.04-1.36)* 1.19(0.99-1.44)
Cancer site
Lung 814/1018 277/426 380/443 157/149 1.27(0.63-2.61) 1.09(0.63-1.89) 1.27(0.82-1.95)
Colorectal 734/747 288/366 362/310 84/71 1.50(0.96-2.33) 1.52(0.95-2.42) 1.15(0.73-1.81)
Breast 5274/7874 2544/3848 2204/3331 526/695 1.44(0.82-2.55) 1.07(0.93-1.24) 1.15(0.73-1.81)
Other 1396/1526 641/734 621/636 134/156 1.04(0.79-1328) 1.12(0.96-1.31) 0.97(0.73-1.30)
Ethnicity
Caucasian 5751/8345 2804/4199 2417/3463 530/683 1.29(1.27-1.63)* 1.17(1.02-1.34)* 1.19(0.98-1.45)
Asian 2253/2423 867/989 1055/1086 331/348 1.27(0.83-1.93) 1.24(0.93-1.66) 1.10(0.76-1.59)
Mixed 214/397 79/186 95/171 40/40 1.34(0.14-12.95) 0.87(0.17-4.40) 1.68(0.44-6.35)
Source of Controls
Population 5549/7936 2590/3777 2388/3387 571/772 1.01(0.89-1.14) 1.02(0.92-1.14) 1.00(0.89-1.13)
Hospital 2556/2930 1114/1426 1128/1219 314/285 1.35(0.97-1.88) 1.21(0.98-1.50) 1.26(0.96-1.65)
Other 113/299 46/171 51/114 16/14 4.25(1.93-9.34)* 1.95(1.25-3.02)* 3.36(1.58-7.13)*
* P<0.05.
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didn’t observe any significant association among other
subgroups (cancer type and source of control) subgroup
in any genetic model using random effect model (Table 2).
Sensitivity analysis
In order to compare the sensitivity of the meta-analysis,
we conducted a leave-one-out sensitivity analysis
(Additional file 1: Table S1). A single study involved in this
meta-analysis was evaluated each time to reflect the influ-
ence of the individual data set to pooled ORs. The results
pattern was not impacted by single study in all genetic
models. The P for Q test and the I2 value also showed that
none of single study affected the heterogeneity of this
meta-analysis.
Statistical uncertainty of finding
For risk assessment, statistical uncertainty is associated
with the model selected [43]. In this meta-analysis, we
evaluated the association of CYP1A2 rs762551 poly-
morphism with cancer risk in different genetic models
(CC versus AA model, dominant model and recessive
model). The results showed the difference among these
genetic models. We found the rs672551 polymorphism
was associated with cancer risk under CC versus AA
model and dominant model, but not under recessive
model.
Bias diagnostics
To evaluate the publication bias of rs762551 variant in
the overall meta-analysis, the funnel plot and Egger’s testwere used. In this analysis, the funnel plot showed a
relatively symmetric distribution (Figure 3), but the point
cloud didn’t have a distinctive form. No publication bias
was detected by the Egger’s test (t = 1.4870, P = 0.1553).
However, the deficient funnel form of the funnel plot
could be due to the relatively high heterogeneity with re-
spect to the different ethnicity and the source of control
population. Furthermore, the number of studies was rela-
tively small and the publication bias may still exist.
Discussion
Various studies provided evidences that genetics play an
important role in determining cancer risk and associ-
ation studies have been identified to evaluate cancer sus-
ceptibility [44]. However, many association studies failed
to provide convincing evidence of linkage and have
resulted in contradicting findings, especially in small
sample sizes [45]. Meta-analysis provided a popular
method for combining world literatures across studies to
resolve the statistical power and discrepancy problem in
associate studies [46]. Based on 19 studies providing
data on CYP1A2 rs762551 polymorphism and cancer
risk, we conduced a meta-analysis involving in 8218 can-
cer cases and 11165 controls to indicate if the rs762551
polymorphism was significantly associated with risk of
cancer. We evaluated the publication bias. The CYP1A2
rs762551 A>C genotypes funnel plot was approximately
symmetrical and the Eggle’s test showed that there is no
publication bias in the study of CYP1A2 rs762551 (P =
0.1553). We found that the carriers of CYP1A2 rs762551
C allele had a weak effect on the overall cancer risk in
Figure 2 Forest plot of cancer risk associated with CYP1A2
rs762551 polymorphism in different ethnicity. Pooled odds ratio
(OR) for (1) total samples, (2) Caucasians ethnicity, and (3) Asians
ethnicity. The genetic models are CC versus AA. The squares and
horizontal lines correspond to the study-specific odds ratio (OR) and
95% confidence interval (CI).
Figure 3 Funnel plot analysis to detect publication bias for
rs762551 polymorphism (CC versus AA). Each point represents an
individual study for the indicated association.
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These results suggested that the CYP1A2 rs762551 poly-
morphism might be useful for assessing cancer risk.
CYP1A2 is a critical enzyme involved in drug metabo-
lism and carcinogen bioactivation. The expression and
activity of CYP1A2 has been demonstrated to relate to
the risk of various cancers [2,6,41,47]. CYP1A2 gene is
genetically polymorphic in human. To date, 177 SNPs
have been deposited in the NCBI database and the fre-
quency of these SNPs varies by ethnicity. Many of these
SNPs are in linkage disequilibrium and a few SNPs have
been reported to be functional [14,48]. For example,
CYP1A2*1F (rs762551) polymorphism can result in 2–3
fold increase in activity/protein and has been associated
with inducibility [49]. Our current analysis showed that
the CC genotype of rs762551 elevated the individual sus-
ceptibility to the cancer risk. This is consistent to the
function of CYP1A2 rs762551 polymorphism. However,
we didn’t observe any correction of CC genotype with
the cancer risk in subgroup analysis by cancer type. This
biochemical mechanism was still unclear. In addition,
due to the low OR in our study, our results should be
interpreted cautiously. The CYP1A2 polymorphism may
prove to be useful for assessing cancer risk.
It has been well known that cancer occurrence and mor-
tality varied by ethnicity and geographic location [50]. In
this meta-analysis, all subjects were subgrouped into three
groups (Caucasian, Asian and other populations). No
association of rs762551 polymorphism with cancer risk
was detected in Asian and mixed population, while
increased cancer risk was demonstrated in Caucasians.
This finding reflected the difference of cancer susceptibility
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and environmental exposure. However due to the low OR
in this meta-analysis, further investigation still need to
be conducted in a large scale Asian population.
Any meta-analysis has it limitations. To better interpre-
ting the finding, several limitations need to be considered
in current analysis. Firstly, potential publication biases
may exist in this meta-analysis because studies excluded
the non-English-language publications. Secondly, the total
study size was still too small to perform subgroup analysis.
Thirdly, this meta-analysis was based on unadjusted data
due to a lack of detailed genotype information stratified by
main confounding variables, such as gender, age, smoking
status in original articles.
Conclusions
In summary, our meta-analysis demonstrated a weak
association of CYP1A2 rs762551 polymorphism with
cancer risk, mainly in Caucasian population. However,
as a potentially powerful tool for assessing population
effects of genetic variants, meta-analysis cannot replace
for adequate genetic association studies. Also, to reach a
more definitive conclusion, further gene-gene interaction
and gene-environment interaction studies, which based
on large sample size, are still needed in different
population.
Additional file
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